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Summary
A novel heteroplasmic 7587TrC mutation in the mi-
tochondrial genome which changes the initiation codon
of the gene encoding cytochrome c oxidase subunit II
(COX II), was found in a family with mitochondrial
disease. This TrC transition is predicted to change the
initiating methionine to threonine. The mutation load
was present at 67% in muscle from the index case and
at 91% in muscle from the patient’s clinically affected
son. Muscle biopsy samples revealed isolated COX de-
ficiency and mitochondrial proliferation. Single-muscle-
fiber analysis revealed that the 7587C copy was at much
higher load in COX-negative fibers than in COX-posi-
tive fibers. After microphotometric enzyme analysis, the
mutation was shown to cause a decrease in COX activity
when the mutant load was 155%–65%. In fibroblasts
from one family member, which contained 195% mu-
tated mtDNA, there was no detectable synthesis or any
steady-state level of COX II. This new mutation con-
stitutes a new mechanism by which mtDNA mutations
can cause disease-defective initiation of translation.
Introduction
Mitochondrial cytopathies are a heterogeneous group of
clinical disorders affecting predominantly muscle and
nerve but can cause a variety of different symptoms and
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signs (Johns 1995; Chinnery and Turnbull 1997; Schon
et al. 1997). In many patients the genetic defect involves
mtDNA and takes the form of rearrangements or point
mutations (Wallace 1992; DiMauro and Moraes 1993).
Point mutations may involve either RNA or protein-
encoding genes, the former group beingmuchmore prev-
alent, with 140 separate mutations already identified
(Johns 1995). Much less common are point mutations
that alter the protein-coding genes, such as complex
I–gene mutations that result in Leber hereditary optic
neuropathy (LHON; Wallace et al. 1988; Howell et al.
1991a), or point mutations in the ATPase 6 gene that
results in neurogenic muscular weakness, ataxia, and
retinitis pigmentosa (Holt et al. 1990).
The site of an mtDNA mutation provides key infor-
mation about the mechanism by which the mutation
causes a biochemical defect. Pathogenic point mutations
involving tRNA genes impair mitochondrial protein syn-
thesis in a general fashion; those in protein-coding genes
may affect the catalytic activity or stability of a respi-
ratory-chain complex. In a family in which affected
members have a mitochondrial encephalomyopathy, we
have identified a mutation in the initiation codon of the
cytochrome c oxidase subunit II (COX II) gene, in which
a TrC substitution is predicted to change methionine
to threonine. The mutation was shown to be present at
67% inmuscle from the index case and at 91% inmuscle
and at 36% in blood from her son, who is more severely
affected. We suggest that this mutation may represent a
novel disease mechanism for mtDNA defects—the im-
pairment of translation initiation of this integral subunit
of COX.
Patients and Methods
Patients
Index case I-1, the mother of the family, is a 57-year-
old woman of normal intellect with a 5–10-year history
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Table 1
Respiratory Chain Complex–Activity in Muscle Mitochondria
COMPLEX
ACTIVITY IN MUSCLE MITOCHONDRIAa
Controlb
( )n  10 Patients
Complex I 229.376.4 308.1
Complex II 351.5113.2 425.5
Complex III 1268.3355.5 1,330.0
Complex IV 1.11.33 .42
Citrate synthase 907.8255.1 1,147.8
NOTE.—Values for control are mean and standard deviation of 10
control subjects.
a Activities and substrates are as follows: citrate synthase, activity
expressed as mmol 5-thio-2-nitrobenzoate produced/min/mg mito-
chondrial protein; complex I, rotenone-sensitive NADH ubiquinone
oxido-reductase activity expressed as NADH oxidized/min/mg mito-
chondrial protein; complex II, activity expressed as nmol 2,6-DCPIP
(dichlorophenolindophenol) reduced/min/mg mitochondrial protein;
and complex III and complex IV, activity expressed as an apparent
first-order rate constant (s/mg mitochondrial protein) for COX re-
duction or oxidation, respectively.
b Data are mean  SD.
Figure 1 Chromatogram from fluorescent M13 sequencing. Se-
quence shows nt 7578–7597. An arrow represents the heteroplasmic
TrC transition at position 7587.
of fatigue and unsteadiness of gait. There was no clinical
evidence of retinal disease, deafness, muscle weakness,
or cardiac disease. Case II-1 is a 30-year-old asympto-
matic man. This patient declined any investigation. Case
II-2 is a 34-year-old man who is severely affected. Al-
though normal at birth and in early childhood, at age
5 years he developed progressive gait ataxia. This pro-
gressed so that he became wheelchair bound by age 25
years. Neuropsychometric testing showed that he was
severely cognitively impaired. Clinical examination re-
vealed bilateral optic atrophy, pigmentary retinopathy,
a marked decrease in color vision, andmild distal-muscle
wasting. Results of routine biochemical and hematologic
evaluations were normal.
Respiratory Chain–Complex Analysis
Amitochondrial fraction was isolated from freshmus-
cle, obtained by needle biopsy from the index case. The
activities of the individual respiratory-chain complexes
and citrate synthase were determined spectrophoto-
metrically as described elsewhere (Birch-Machin et al.
1994).
Histological and Histochemical Analysis
Transversely orientated blocks were frozen in isopen-
tane and were cooled to 150C with liquid nitrogen.
Sections (10 mm) were cut for hematoxylin and eosin
labeling. Histochemical studies were done on either 8-
mm or 30-mm sections (for use in subsequent single-fiber
PCR analysis). We assayed COX activity by using a me-
dium containing 4 mM 3,3′-diaminobenzidine tetrahy-
drochloride and 100 mM cytochrome c in 0.1 mM phos-
phate (pH 7.0) at 25C. Succinate dehydrogenase
activity was assayed with 1.5 mM nitroblue tetrazolium,
130 mM sodium succinate, 0.2 mM phenazine metho-
sulfate, and 0.1 mM sodium azide in 0.1 mM phosphate
(pH 7.0) at 25C. Sections were stained with the Gomori
trichrome stain, as described by Engel and Cunningham
(1963).
Microphotometric Enzyme Analysis
Microphotometric enzyme analysis was done on 8-
mm sections as described elsewhere (Johnson et al. 1993);
COX-deficient fibers were those with COX activity be-
low the lower limit of the normal range for that partic-
ular fiber type (Johnson et al. 1993). Zero activity was
defined as increase in absorbance (DA450/s) in the pres-
ence of the COX inhibitor (sodium azide [2.5 mM]).
Myoblast and Fibroblast Culture
Myoblast cultures were obtained as described else-
where (Clark et al. 1997). Fibroblast cultures were ob-
tained by explant culture from skin biopsy samples.
Myoblasts were grown in Hams F10 (Gibco BRL Life
Technologies), supplemented with 20% FCS and 1%
chick-embryo extract (ICN Flow Biomedicals). Fibro-
blasts were grown in EMEM (Sigma), supplemented
with 10% FCS. Both growth media were supplemented
with sodium pyruvate (110 mg/ml) and uridine (50 mg/
ml), which are required for growth of respiration-defi-
cient cells (King and Attardi 1989).
Isolation and Sequencing of mtDNA
Total DNA was isolated from muscle (frozen in liquid
nitrogen and ground into a fine powder), leukocytes (iso-
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Figure 2 Schematic illustrating the position of the 7587C mu-
tation within the mitochondrial genome, as well as the associated
amino acid change. The initiation codon of COX II is changed to
threonine. Initiation of translation could occur either at the next ini-
tiation site (AUG), which is “out of frame” and would yield a five-
residue polypeptide, or at the next “in-frame” initiation site (AUA),
16 codons downstream.
lated by centrifugation of the plasma layer), and cultured
cells. Muscle homogenate or cell pellets were resus-
pended in 10 mM Tris HCl (pH 8.0), 1 mM EDTA, 1%
SDS, and 20 mg proteinase K/ml and were left at 37C
overnight. Standard phenol/chloroform extraction and
ethanol precipitation were then done. We performed se-
quencing using M13-tailed primers and dye-primer se-
quencing with an automated DNA sequencer (model
ABI 373; Perkin Elmer/ABI).
Quantification of Mutated mtDNA
Sections of 30 mm or 8 mm were dual stained for suc-
cinate dehydrogenase and COX activities. Single-fiber
PCR was then done as described elsewhere (Sciacco et
al. 1994). Either COX-positive (stained brown) or COX
deficient (stained blue) fibers were isolated and placed
in an individual microfuge tube containing 10 ml dH2O.
After centrifugation and removal of the water, each fiber
was lysed by the addition of 10 ml 200 mM KOH, and
50 mM DTT and was heated to 65C for 1 h. Ten mi-
croliters of neutralizing buffer (900 mM Tris-base, 200
mM HCl) were then added to each tube. PCR analysis
was done directly with 10-ml samples.
Quantification of mutated mtDNA from blood, mus-
cle, cultured cells, and individual muscle fibers was per-
formed as follows: a 385-bp fragment was amplified
with the forward mismatch primer (positions 7565–
7585) 5′ GGCTAAATCCTATATATGTTA 3′ and the re-
verse primer (positions 7949–7931) 5′ TGTAGGAGT-
TGAAGATTAG 3′. PCR cycling conditions were 94C
for 5 min (1 cycle); 94C for 1 min, 50C for 1 min,
and 72C for 1 min (30 cycles); and 72C for 8 min (1
cycle). After further addition of 30 pmol of each primer,
1 U Taq polymerase, and 2.5 mCi a[32P]-dCTP (3,000
Ci/mmol; Amersham), the products were submitted to
a single cycle of 94C for 8 min, 50C for 2 min, and
72C for 12 min. Samples were then extracted with phe-
nol/chloroform and diluted to 100 cpm/ml. Ten microl-
iters were digested with 10 U HincII. Digests were elec-
trophoresed through a 3% Metaphor agarose gel (FMC
Bioproducts), dried onto a support, and analyzed on a
PhosphorImager system with ImageQuant software
(Molecular Dynamics). The mismatch primer creates an
additionalHincII site in the PCR product in the presence
of the mutation. On digestion, wild-type mtDNA will
cut only once, to produce 94-bp and 291-bp fragments.
In the presence of the mutation, however, the 291-bp
fragment is further cleaved, yielding fragments of 19 bp
and 272 bp. Because the 19-bp fragment is lost from
the gel, final calculations of mutant load were normal-
ized for relative levels of cytosine in each visible frag-
ment. The use of a mismatch primer is a widely used
and accepted method of generating a mismatch when
no suitable restriction enzyme is available. Results from
a mismatch primer have been shown to be consistent
with other methods of quantification (Shoffner et al.
1990).
Quantification of mutated mtDNA in muscle, blood,
and fibroblasts of patient II-2 was done by fluorescent
dUTP added to the last PCR cycle. The digested PCR
products were then separated onto a 6% nondenaturing
polyacrylamide gel and were analyzed with GeneScan
software (Perkin Elmer/ABI) (Chalmers et al. 1997).
Mitochondrial Protein Translation
Protein translation was performed according to the
method described by Chomyn (1996). Fibroblasts were
grown in a 25-cm2 flask until 80% confluent and in-
cubated at 37C for 2 h with 1 ml labeling medium
(methionine/cysteine-free DMEM, 10% dialyzed FBS,
10 mg emetine/ml, and 500 mCi [35S]-methionine/cysteine
[3,000 Ci/mmol; Amersham]). After removal of the in-
cubation medium, the cells were washed in PBS and a
cell pellet was prepared. Protein samples containing
50,000 disintegrations per minute were separated onto
a 12% polyacrylamide (Prosieve 50; Flowgen) SDS gel.
Products were visualized with a PhosphorImager system
(Molecular Dynamics).
Immunoblot Analysis of Cultured Skin–Fibroblast
Protein
Total cellular protein (50 mg) was separated onto a
15% SDS polyacrylamide gel and was transferred to
Immobilon polyvinylidene difluoride membrane (Milli-
pore) by electroblotting, with use of a minitransfer sys-
tem (Hoefer Scientific). The membrane was blockedwith
a 5% milk solution prior to addition of antibodies. In-
cubations with primary antibodies (monoclonal to COX
II, polyclonal to COX subunit IV [COX IV], and cro-
tonase) were done for 2 h at room temperature. Rabbit
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Table 2
mtDNA Changes from the Index Case Compared with the Reference Sequence
Base Change Gene a State
Amino Acid
Change Previous Reportsb
7028CrT COX I Homoplasmic None Previously identified polymorphism
14798TrC cyt b Homoplasmic Phenylalanine
to leucine
Previously identified polymorphism
10084TrC ND3 Homoplasmic Isoleucine to
threonine
Not previously identified
9655GrA COX III Homoplasmic Serine to
asparagine
Not previously identified
7587TrC COX II Heteroplasmic Methionine
to threonine
Not previously identified
a ND  NADH ubiquinone oxido-reductase; cyt b  apo cytochrome-b.
b Previous identification was made on the basis of data obtained from the MITOMAP database.
antimouse IgG horseradish peroxidase (HRP) and goat
antirabbit IgG HRP–conjugated secondary antibodies
were used. The proteins were detected with an enhanced
chemiluminescence kit (Amersham).
Northern Blot Analysis
We isolated total cytosolic RNA directly from 2–3#
106 cells by using the total RNA isolation kit, Ultraspec
RNA (Biotecx). RNA (18 mg) was separated onto a 1.2%
agarose gel containing 2.5% formaldehyde and was
transferred to GeneScreen-plus (NEN DuPont)
membrane by standard capillary technique. Regions of
mtDNA were amplified by PCR to produce probes for
northern blots. We generated the COX II probe by am-
plifying a region spanning nucleotides (nt) 7405–8364,
digesting the product with MboII, and extracting the
280-bp fragment from agarose gels. We generated the
NADH ubiquinone oxido-reductase subunit 4 (ND4)
probe by amplifying the region that spanned nt
11579–12419, cleaving it with SpeI, and extracting the
380-bp fragment from agarose gels. A 1.2-kb b-actin
probe was generated as described by Gunning et al.
(1983). Radiolabeling was performed by the random-
primer method, supplemented with 100 mM of each nu-
cleotide, 25 mCi[32P]-dCTP (3,000 Ci/mmol; Amer-
sham), and 1 U Klenow fragment (Boehringer-Mann-
heim). Unincorporated nucleotides were removed from
the sample by gel filtration (Sepadex G-50 DNA grade;
Pharmacia). All incubations were done in a rotating Hy-
baid tube (Hybaid). Prehybridization was done at 42C
for 2 h by incubation of the membrane with hybrid-
ization solution (5# SSPE, 50% formamide, 5# Den-
hardt’s solution, 1% SDS). A 1–2 # 106-cpm radiola-
beled probe was used for each 10 ml of hybridization
solution, which we denatured by boiling it for 2–5 min
in a water bath before adding it directly to the hybrid-
ization solution. Hybridization was then done at 42C
overnight. Two 15-min washes were initially done at
room temperature with 2 # SSPE, followed by a 15-
min wash at 65C with 2 # SSPE and 2% SDS. The
blots subsequently were subjected to PhosphorImager
analysis.
Results
Activity of Respiratory-Chain Complexes
COX complex IV activity was 35% of control values
in the mitochondrial fraction from muscle from the in-
dex case. Activity of the other complexes was within the
normal range (table 1).
Muscle Histochemistry
For the index case, ∼l5% of fibers contained subsar-
colemmal accumulation of mitochondria (ragged red fi-
bers), as determined by intense succinate dehydrogenase
reactivity at the periphery of the fiber.Microphotometric
analysis revealed that only 30% of fibers had COX ac-
tivity within the normal range, 30%–40% of fibers were
COX negative (activity could not be distinguished from
background levels), and the others had intermediate ac-
tivity (i.e., were COX deficient). The clinically affected
son was shown to have 80% COX-negative fibers, and,
on Gomori trichrome staining, ∼50% of fibers showed
subsarcolemmal accumulation of mitochondria.
Detection of a Heteroplasmic TrC Mutation by
Automated DNA Sequencing
No mtDNA rearrangement was observed on Southern
blot analysis (data not shown). The presence of ragged
red fibers and a mosaic of COX-positive and -negative
fibers on histochemical analysis of the muscle were con-
sistent with a tRNA mutation. On direct sequencing,
however, no base change from the reference sequence
(Anderson et al. 1981) was found in any of the 22 tRNA
genes. Because of the compact nature of the mitochon-
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Figure 3 Quantification of the 7587C mutation in muscle, cultured fibroblasts, and cultured myoblasts from the index case. PCR and
RFLP were done as described in Patients and Methods, and products were electrophoresed through a 3% Metaphor agarose gel. The levels of
mutated mtDNA are represented as percentages of total mtDNA and are shown (bottom). To separate the 291-bp and 272-bp bands, it was
necessary to run the 94-bp and 19-bp fragments off the bottom of the gel.
drial genome and the absence of introns, the protein-
coding genes are not markedly separated from the tRNA/
rRNA genes. Thus we obtained the sequence of the start
of the COX II gene when analysis of the tRNASer(UCN)
and tRNAAsp genes was undertaken. A heteroplasmic
TrC transition was found at nt position 7587 (fig. 1),
in the second base of the first codon of the gene encoding
COX II (fig. 2). This mutation is predicted to change
the initiating methionine to threonine. No other heter-
oplasmic base changes were found in this gene or in any
of the other mitochondrial-encoded COX genes. Four
homoplasmic base changes, compared with the stan-
dard sequence (Anderson et al. 1981)—14798TrC,
9655GrA, 7028CrT, and 10084TrC—were found
within the protein-coding genes. The predicted outcome
of these base changes is summarized in table 2.
Quantification of the 7587C Mutation in the Index
Case and Her Affected Son
Although, on the basis of the sequence data, it ap-
peared that the mutation was heteroplasmic, we wanted
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Figure 4 Distribution of the 7587C mutation in single fibers expressing either a COX-positive or -negative phenotype. The levels of
mutated mtDNA are represented as percentages of total mtDNA and are shown underneath. To separate the 291-bp and 272-bp bands, it was
necessary to run the 19-bp fragment off the bottom of the gel.
Figure 5 Threshold of the 7587C mutation. Microphotometric
enzyme analysis and single-fiber PCR were performed on adjacent 8-
mm serial sections as described in Patients and Methods. Values for
COX activity are represented as DA450nm # 10
5/s.
to determine the level of mutated and wild-typemtDNA.
The level of the mutation was shown to be 67% in
muscle from the index case and 52% in fibroblasts but
was undetectable in blood and cultured myoblasts (fig.
3). Subsequent investigation of patient II-2 revealed the
presence of the 7587C allele at 91% in muscle, 36% in
blood, and 89% in cultured fibroblasts. The 7587C al-
lele, however, increased to homoplasmic levels in fibro-
blasts after substantial culturing.
Correlation of the Mutation with a Biochemical Defect
To investigate whether the 7587Cmutation correlated
with COX deficiency, COX-positive and -negative single
fibers were isolated from a 30-mm section of muscle from
the index case (I-1). In COX-positive fibers, 17%–52%
of alleles were mutant; in COX-negative fibers, wild-
type alleles were undetectable (fig. 4). The COX-negative
fibers picked at this stage of investigation were the most
intensely blue stained (ragged red and non–ragged red
fibers) and thus the most severely affected biochemically.
Determination of the Biochemical Threshold for the
7587C Mutation
Because it is possible that the 7587C allele results in
a novel disease mechanism, we wanted to investigate
whether there was either a relationship between mutant
load and biochemical activity or a threshold. To deter-
mine the level at which the 7587C mutation induced a
biochemical defect, COX activity was measured and sin-
gle-fiber PCR was performed on serial 8-mm muscle sec-
tions. COX activity was severely impaired when 55%–
65% of the mtDNA was mutated (fig. 5).
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Figure 6 Mitochondrial protein synthesis in fibroblasts. Fibro-
blasts were cultured in the presence of 10 mg emetine/ml and were
pulse labeled for 30 min (lanes 1 and 2) or 2 h (lanes 3 and 4) with
500 mCi 35S methionine/cysteine. Products were separated through a
1.2% polyacrylamide gel as described in Patients and Methods. Prod-
ucts were labeled according to molecular weight and findings from
products from previously reported in vivo translation assays (Chomyn
1996). ND  NADH ubiquinone oxido-reductase; cyt b  apo cy-
tochrome-b; and ATPase  ATP synthase.
Figure 7 Immunoblotting of whole-cell lysate. Equal amounts
(15 mg) of protein were subjected to SDS PAGE and were blotted onto
a polyvinylidene difluoride membrane as described in Patients and
Methods. A, Incubation with a monoclonal COX II antibody, dem-
onstrating absence of COX II in patient II-2 fibroblasts. B, Incubation
with a polyclonal antibody to COX IV. Patient II-2 fibroblasts contain
half the amount of COX IV, compared with that in the control. C,
Incubation with a polyclonal antibody to crotonase, demonstrating
that the results shown inA are not due to a variation in protein loading.
The more intense signal obtained from patient II-2 fibroblasts suggests
that there is either up-regulation of crotonase or slightly more protein
in this lane compared with that in the control fibroblasts. High-mo-
lecular-weight species represent nonspecific proteins recognized by the
crotonase antisera. Molecular-weight markers were included on the
gel to check product sizes.
Mitochondrial Translation Products
Two methods were employed to investigate the effect
of the 7587C mutation on expression of the COX II
protein. For these studies, we used fibroblasts from pa-
tient II-2 that had, on continued culture, become vir-
tually homoplasmic for mutated mtDNA. Translation of
mitochondrial-encoded proteins demonstrated that no
full-length COX II protein was present (fig. 6). Levels
of all other translation products were similar in patient
and control fibroblasts. Immunoblotting with a mono-
clonal antibody to the COX II did not detect this subunit
in fibroblasts from patient II-2 (fig. 7A). Immunoblotting
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Figure 8 Northern blot hybridization analysis. Equal amounts
(18 mg) of RNA were separated onto a 1.2% agarose gel containing
2.5% formaldehyde and were transferred to a nitrocellulose
membrane, and mitochondrial and nuclear probes were constructed
and radiolabeled as described in Patients and Methods. Hybridization
was done with a 280-bp COX II probe, a 1.2-kb b-actin probe, and
a 380-bp ND4-specific probe. The steady-state level of COX II mRNA
in patient II-2 is one-third of that in controls.
with an anti–COX IV antibody demonstrated that half
the amount of this subunit is present in patient II-2 fi-
broblasts, compared with control fibroblasts (fig. 7B).
Determination of Steady-State mRNA Levels
Northern blot hybridization with specific probes to
transcripts encoding COX II, ND4, and b-actin was used
to determine the steady-state levels of the respective
mRNAs in patient II-2’s fibroblasts (fig. 8). Using b-actin
as a guide, we determined that there was slightly more
mRNA present in the control lane than in the patient
lane (fig. 8). The ratio of ND4 transcript to b-actin was
the same in the two cell lines, whereas there was a 2.3-
fold decrease in the level of COX II mRNA (fig. 8). This
result was confirmed by RNA prepared from cells grown
on two separate occasions.
Discussion
We have described a family with an mtDNAmutation
within the start codon of the gene encoding COX II.
The mother sought medical opinion because she was
aware that mitochondrial disease may be transmitted
maternally and because of concern about her unaffected
son. She was not aware of her own neurological diffi-
culties at the time of her presentation. The family dem-
onstrates the extreme variability in symptoms seen in
patients with heteroplasmic mtDNA mutations. In ad-
dition, it confirms the difficulty in giving genetic advice
to women with heteroplasmic mtDNA point mutations.
Our patient has one child who developed severe neu-
rological symptoms starting at age 5 years, whereas the
other son is clinically unaffected at age 30 years. We
suggest that this mutation is pathological for the follow-
ing reasons: (1) it is heteroplasmic; (2) it results in an
animo acid change at a functionally important site; (3)
it segregates with a biochemical defect; and (4) the mo-
lecular nature of the mutation is consistent with the find-
ings of biochemical, histochemical, protein translation,
and mRNA analysis, in which translation initiation is
impaired.
We sequenced the majority of the mitochondrial ge-
nome from the index case and found a number of other
changes, compared with the Cambridge reference se-
quence (Anderson et al. 1981). 7028C/T (Torroni et al.
1996) and 14798T/C (Brown et al. 1992) are recognized
polymorphisms. A previously unreported homoplasmic
change was detected in ND3 (10084TrC), which is pre-
dicted to alter an amino acid but could not account for
the biochemical defect. The base change in the gene en-
coding COX subunit III (COX III; 9655GrA) has not
been reported. This mutation is more difficult to explain,
because it is not only predicted to change an amino acid,
but it also involves a conserved residue. The base change,
however, is homoplasmic in blood and muscle, and, al-
though this certainly does not exclude pathogenicity, it
makes it less likely. A homoplasmic change could not
explain the muscle-histochemistry findings with the pres-
ence of COX-positive and -negative fibers. The corre-
lation of the 7587C mutant load with the loss of COX
activity in individual muscle fibers is very important in
the determination of whether a mutation is pathogenic.
The presence of the 9655A mutation calls attention
to two issues. First, it stresses how difficult it is to define
the pathogenic basis of mtDNA mutations, even if they
apparently occur at important sites. The criteria that can
be used to confirm pathogenicity are evidence of seg-
regation of the genetic defect with disease within a ped-
igree, such as in the case of LHON (Wallace et al. 1988;
Howell et al. 1991a; Johns et al. 1992), or correlation
with a biochemical defect, such as in the case of COX-
negative fibers (Weber et al. 1996). Second, others have
suggested that secondary mutations may influence the
expression of a primary mutation (Howell et al. 1991b;
Torroni et al. 1997). It seems unlikely in this case that
9655A could be influencing the expression of 7587C,
because the latter mutation occurs in the initiation codon
of an open reading frame; however, this possibility can-
not be discarded.
1338 Am. J. Hum. Genet. 64:1330–1339, 1999
We have been unable to detect mature COX II poly-
peptide in patient II-2 fibroblasts with a near-homo-
plasmic level of the 7587C mutation. The implication
for the absence of a start codon at this position is either
that translation begins at another initiation site or that
no translation occurs at all. If translation initiates from
the next initiation site, a short polypeptide of five resi-
dues is predicted to be generated. If translation initiates
at the next “in-frame” initiation site, a truncated poly-
peptide lacking the N-terminal 16 residues would be
produced. Since the epitope recognized by the COX II
antibody has not been mapped, it is a formal possibility
that the absence of reactivity on the western blot could
be a result of the epitope being within this N-terminal
sequence. No truncated protein was detected, either by
immunoblotting or by comparison of total mitochon-
drial protein synthesis in control versus patient cells.
Therefore, we believe that the results are consistent with
the absence of translation of COX II mRNA carrying
the 7587C mutation in the initiation codon.
COX II mRNA levels were shown to be substantially
lower in patient II-2 fibroblasts. In the absence of trans-
lation, the mutated mRNA species will presumably be
vulnerable to degradation.We therefore propose that the
inability to translate the COX II transcript at the correct
initiation codon results in more-rapid degradation of
mRNA.
An alternative disease mechanism for the T7857Cmu-
tation is impaired cleavage of the tRNAAsp. This would
result in a relative tRNA deficiency and thus impair the
translation of all mitochondrial-encoded proteins. For
the reasons highlighted above, and since the activity of
complex I and complex III was normal in the index case,
we think that this is highly unlikely.
Measurement of the threshold for specific mtDNA
mutations has been performed in cultured cells elsewhere
(Boulet et al. 1992; Bentlage and Attardi 1996; Villani
and Attardi 1997). The microphotometric enzyme–assay
system for measurement of COX activity within indi-
vidual muscle fibers (Johnson et al. 1993) is used in
conjunction with demonstration of myofibrillar ATPase
in serial sections, so that a normal range of COX activity
in individual muscle fibers of each fiber type is defined
in control samples. In previous studies, a good corre-
lation between microphotometric enzyme analysis and
biochemical studies has been shown in patients with
Leigh syndrome (Johnson et al. 1993). We measured
COX activity and performed single-fiber PCR on adja-
cent muscle sections to determine the biochemical
threshold (the percentage of mutated mtDNA required
to cause a biochemical defect) for the 7587C mutation.
Analysis of affected tissue will reflect the situation in
vivo. The relative level of mutated versus wild-type
mtDNA required to produce a COX-deficient phenotype
was 55%–65%. No fiber that had a high mutant load
demonstrated normal activity; this was also shown in
the initial single-fiber analysis, in which the highest level
of mutated mtDNA found in COX-positive fibers was
52%. The threshold phenomenon is common in heter-
oplasmic mtDNA mutations, with the level of mutated
mtDNA required to induce a biochemical deficit varying
for different mutations. For tRNA mutations, this level
is usually 185% (Bentlage and Attardi 1996), because
the mutated tRNA is partially active. Enriquez et al.
(1995) have reported that cybrids homoplasmic for the
8344G mutation still have aminoacylated tRNALys mol-
ecules, albeit at reduced levels. Thus, partial activity is
believed to explain the remarkably recessive nature of
tRNA mutations. The newly reported 7587C mutation
appears to prevent translation of COX II, ruling out the
possibility of generation of a partially active product and
possibly explaining why this biochemical threshold oc-
curs at lower mutant loads.
It is not known exactly how COX is assembled, but
there is evidence that mitochondrial-encoded subunits II
and III are involved initially (Wielburski et al. 1982;
Wielburski and Nelson 1983). It is therefore possible
that a critical level of these subunits is required before
any holoenzyme is assembled. This would account for
the absence of COX activity, even in the presence of
35%–45% wild-type mtDNA.
To conclude, we have identified a novel pathogenic
mtDNA point mutation in the initiation codon of COX
II. We have demonstrated that this mutation results in
an inability to express COX II protein, causing a specific
decrease in COX activity.
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